Biomedical scientists reports a drug -- an estrogen receptor ligand called indazole chloride (IndCl) -- has the potential to improve vision in patients with multiple sclerosis, or MS. The study was performed on mice induced with a model of MS and the first to investigate IndCl's effect on the pathology and function of the complete afferent visual pathway.